Literature DB >> 20490982

Heterogeneity of the tumor vasculature.

Janice A Nagy1, Sung-Hee Chang, Shou-Ching Shih, Ann M Dvorak, Harold F Dvorak.   

Abstract

The blood vessels supplying tumors are strikingly heterogeneous and differ from their normal counterparts with respect to organization, structure, and function. Six distinctly different tumor vessel types have been identified, and much has been learned about the steps and mechanisms by which they form. Four of the six vessel types (mother vessels, capillaries, glomeruloid microvascular proliferations, and vascular malformations) develop from preexisting normal venules and capillaries by angiogenesis. The two remaining vessel types (feeder arteries and draining veins) develop from arterio-venogenesis, a parallel, poorly understood process that involves the remodeling of preexisting arteries and veins. All six of these tumor vessel types can be induced to form sequentially in normal mouse tissues by an adenoviral vector expressing vascular endothelial growth factor (VEGF)-A164. Current antiangiogenic cancer therapies directed at VEGF-A or its receptors have been of only limited benefit to cancer patients, perhaps because they target only the endothelial cells of the tumor blood vessel subset that requires exogenous VEGF-A for maintenance. A goal of future work is to identify therapeutic targets on tumor blood vessel endothelial cells that have lost this requirement. Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20490982      PMCID: PMC3278036          DOI: 10.1055/s-0030-1253454

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  56 in total

Review 1.  Vasculogenic mimicry: how convincing, how novel, and how significant?

Authors:  D M McDonald; L Munn; R K Jain
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery.

Authors:  C Sundberg; J A Nagy; L F Brown; D Feng; I A Eckelhoefer; E J Manseau; A M Dvorak; H F Dvorak
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers.

Authors:  Oddbjørn Straume; Pierre O Chappuis; Helga B Salvesen; Ole J Halvorsen; Svein A Haukaas; John R Goffin; Louis R Bégin; William D Foulkes; Lars A Akslen
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

4.  Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.

Authors:  Qi Xue; Janice A Nagy; Eleanor J Manseau; Thuy L Phung; Harold F Dvorak; Laura E Benjamin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-05-14       Impact factor: 8.311

5.  Transretinal feeder vessel ligature in von Hippel-Lindau disease.

Authors:  M E Farah; F Uno; A L Höfling-Lima; P H Morales; R A Costa; J A Cardillo
Journal:  Eur J Ophthalmol       Date:  2001 Oct-Dec       Impact factor: 2.597

6.  Morphological characteristics of the microvasculature in healing myocardial infarcts.

Authors:  Guofeng Ren; Lloyd H Michael; Mark L Entman; Nikolaos G Frangogiannis
Journal:  J Histochem Cytochem       Date:  2002-01       Impact factor: 2.479

Review 7.  Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology.

Authors:  G L Semenza
Journal:  Trends Mol Med       Date:  2001-08       Impact factor: 11.951

8.  Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis.

Authors:  William P J Leenders; Benno Küsters; Robert M W de Waal
Journal:  Endothelium       Date:  2002

Review 9.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

Authors:  Napoleone Ferrara
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

10.  Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.

Authors:  Janice A Nagy; Eliza Vasile; Dian Feng; Christian Sundberg; Lawrence F Brown; Michael J Detmar; Joel A Lawitts; Laura Benjamin; Xiaolian Tan; Eleanor J Manseau; Ann M Dvorak; Harold F Dvorak
Journal:  J Exp Med       Date:  2002-12-02       Impact factor: 14.307

View more
  122 in total

1.  Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Authors:  Basel Sitohy; Janice A Nagy; Shou-Ching Shih Jaminet; Harold F Dvorak
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

Review 2.  Endothelial cell heterogeneity.

Authors:  William C Aird
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 3.  Targeting angiogenesis in gynecologic cancers.

Authors:  Behrouz Zand; Robert L Coleman; Anil K Sood
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

Review 4.  Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.

Authors:  Sophie Marchal; Amélie El Hor; Marie Millard; Véronique Gillon; Lina Bezdetnaya
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

Review 5.  In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles.

Authors:  Altug Ozcelikkale; Hye-Ran Moon; Michael Linnes; Bumsoo Han
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-14

Review 6.  Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells.

Authors:  Muriel Mathonnet; Aurelie Perraud; Niki Christou; Hussein Akil; Carole Melin; Serge Battu; Marie-Odile Jauberteau; Yves Denizot
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 7.  Tumors: wounds that do not heal-redux.

Authors:  Harold F Dvorak
Journal:  Cancer Immunol Res       Date:  2015-01       Impact factor: 11.151

Review 8.  Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.

Authors:  John D Martin; Dai Fukumura; Dan G Duda; Yves Boucher; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

9.  Haploinsufficiency of Klippel-Trenaunay syndrome gene Aggf1 inhibits developmental and pathological angiogenesis by inactivating PI3K and AKT and disrupts vascular integrity by activating VE-cadherin.

Authors:  Teng Zhang; Yufeng Yao; Jingjing Wang; Yong Li; Ping He; Vinay Pasupuleti; Zhengkun Hu; Xinzhen Jia; Qixue Song; Xiao-Li Tian; Changqing Hu; Qiuyun Chen; Qing Kenneth Wang
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

Review 10.  Mouse models for studying angiogenesis and lymphangiogenesis in cancer.

Authors:  Lauri Eklund; Maija Bry; Kari Alitalo
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.